Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junqi Niu

Showing results (261-270 of 280) with videos related to

Pageof 28
Sort By:
Gut|June 24, 2025
Rice-derived recombinant human serum albumin as an alternative to human plasma for patients with decompensated liver cirrhosis: a randomised, double-blind, positive-controlled and non-inferiority trialJunqi Niu, Yanhang Gao, Guiqiang Wang, et al.
Clinical and Molecular Hepatology|January 22, 2025
Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0Di Wu, Jia-Horng Kao, Teerha Piratvisuth, et al.
EMBO Reports|July 10, 2020
The deubiquitinase USP44 promotes Treg function during inflammation by preventing FOXP3 degradationJing Yang, Ping Wei, Joseph Barbi, et al.
Scientific Reports|July 18, 2020
High prevalence of Clonorchis sinensis infections and coinfection with hepatitis virus in riverside villages in northeast ChinaYanhang Gao, Yanqing Li, Xiaowen Liu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 6, 2021
Pradefovir Treatment in Patients With Chronic Hepatitis B: Week 24 Results From a Multicenter, Double-Blind, Randomized, Noninferiority, Phase 2 TrialYanhang Gao, Fei Kong, Xinwen Song, et al.
The Journal of Infection|February 23, 2025
Efficacy and safety of GLS4 with entecavir vs entecavir alone in chronic hepatitis B patients: A multicenter clinical trialMingyuan Zhang, Yanhang Gao, Fei Kong, et al.
Journal of Gastroenterology and Hepatology|October 5, 2013
Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infectionHuiying Rao, Lai Wei, Juan Carlos Lopez-Talavera, et al.
Nature Medicine|November 7, 2025
Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trialGrace Lai-Hung Wong, Man-Fung Yuen, Bingliang Lin, et al.
Emerging Microbes & Infections|November 18, 2022
Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, ChinaHongqin Xu, Hongyan Li, Hailong You, et al.
Journal of Gastroenterology and Hepatology|August 26, 2020
High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3bFanpu Ji, Jie Li, Li Liu, et al.
Pageof 28

Showing results (261-270 of 280) with videos related to

Sort By:
Pageof 28
Gut|June 24, 2025
Rice-derived recombinant human serum albumin as an alternative to human plasma for patients with decompensated liver cirrhosis: a randomised, double-blind, positive-controlled and non-inferiority trialJunqi Niu, Yanhang Gao, Guiqiang Wang, et al.
Clinical and Molecular Hepatology|January 22, 2025
Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0Di Wu, Jia-Horng Kao, Teerha Piratvisuth, et al.
EMBO Reports|July 10, 2020
The deubiquitinase USP44 promotes Treg function during inflammation by preventing FOXP3 degradationJing Yang, Ping Wei, Joseph Barbi, et al.
Scientific Reports|July 18, 2020
High prevalence of Clonorchis sinensis infections and coinfection with hepatitis virus in riverside villages in northeast ChinaYanhang Gao, Yanqing Li, Xiaowen Liu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 6, 2021
Pradefovir Treatment in Patients With Chronic Hepatitis B: Week 24 Results From a Multicenter, Double-Blind, Randomized, Noninferiority, Phase 2 TrialYanhang Gao, Fei Kong, Xinwen Song, et al.
The Journal of Infection|February 23, 2025
Efficacy and safety of GLS4 with entecavir vs entecavir alone in chronic hepatitis B patients: A multicenter clinical trialMingyuan Zhang, Yanhang Gao, Fei Kong, et al.
Journal of Gastroenterology and Hepatology|October 5, 2013
Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infectionHuiying Rao, Lai Wei, Juan Carlos Lopez-Talavera, et al.
Nature Medicine|November 7, 2025
Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trialGrace Lai-Hung Wong, Man-Fung Yuen, Bingliang Lin, et al.
Emerging Microbes & Infections|November 18, 2022
Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, ChinaHongqin Xu, Hongyan Li, Hailong You, et al.
Journal of Gastroenterology and Hepatology|August 26, 2020
High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3bFanpu Ji, Jie Li, Li Liu, et al.
Pageof 28